VERICEL CORP
VCELNASDAQTrading Snapshot
- Day Range
- โ
- 52-Week Range
- $28.95 โ $59.75
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 51.2M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- $276M
- Last Q Revenue
- $85M
- P/E Ratio
- 89.2
- P/S Ratio
- 9.2x
- EPS (TTM)
- $0.59
- Dividend Yield
- โ
VERICEL CORP
VCELFinancial history unavailable.
About VERICEL CORP
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
News unavailable.